Additional perspective on cariprazine and negative symptoms

"Additional perspective on cariprazine and negative symptoms." Expert Opinion on Pharmacotherapy, 23(12), pp. 1469–1470

Declaration of interest

JT. Kantrowitz reports having received consulting payments within the last five years from Alphasights, Charles River Laboratories, Medscape, Putnam, techspert.io, Third Bridge, MEDACorp, Parexel, groupH, Simon Kucher, the ECRI Institute, ExpertConnect, Schlesinger Group, CelloHealth, Acsel Health, Strafluence, Guidepoint, L.E.K., System Analytic, Kinetix Group, Slingshot, Smart Analyst, Transperfect, Anthem, Semantics MR LTD, BVF Partners, LifeSci Capital, Piper Jaffray, IQVIA, and Krog & Partners Incorporated. Furthermore, he has served on the advisory board of Alkermes Aristada Schizophrenia, MedinCell Psychiatry, the Karuna Mechanism of Action (MOA). He has conducted clinical research supported by the National Institute of Mental Health (NIMH), Sunovion, Eli Lilly and Company, Alkermes, Roche, Cerevance, Corcept, Takeda, Taisho, Lundbeck, Boehringer Ingelheim, NeuroRX, and Teva within the last five years. Dr Kantrowitz was a co-investigator on a study that receives lumateperone and reimbursement for safety testing for an investigator-initiated research from Intra-Cellular Therapies Inc. He also owns a small number of shares of common stock from GlaxoSmithKline. He has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This manuscript was not funded.